A review of intravenous immunoglobulin in the treatment of neuroimmune conditions, acute COVID-19 infection, and post-acute sequelae of COVID-19 Syndrome. — CFSMEATLAS
A review of intravenous immunoglobulin in the treatment of neuroimmune conditions, acute COVID-19 infection, and post-acute sequelae of COVID-19 Syndrome.
Morse, Brinkley A, Motovilov, Katherine, Michael Brode, W et al. · Brain, behavior, and immunity · 2025 · DOI
Quick Summary
This review examines intravenous immunoglobulin (IVIG), a treatment that works by providing immune-boosting antibodies, for several conditions including ME/CFS and long COVID. The researchers found that IVIG may help reduce symptoms in some patients, though results have been mixed. The treatment can have side effects and is very expensive, which limits how widely it can be used.
Why It Matters
This review provides a comprehensive overview of IVIG as a potential immunomodulatory therapy for ME/CFS, placing it within the broader context of neuroimmune diseases. Understanding IVIG's mechanisms and mixed efficacy in ME/CFS helps patients and researchers evaluate whether this treatment warrants further investigation and clinical trials. The identification of knowledge gaps highlights the need for optimized patient selection and dosing protocols specific to ME/CFS populations.
Observed Findings
IVIG has demonstrated benefits in reducing mechanical ventilation needs, ICU/hospital stays, and mortality in severe acute COVID-19 when administered early
IVIG has shown symptom alleviation in small patient cohorts with post-acute sequelae of SARS-CoV-2, though research remains in early stages
ME/CFS studies with IVIG have yielded mixed results with variable efficacy outcomes
IVIG carries potential adverse effects including anaphylaxis, headaches, thrombosis, liver enzyme elevation, and renal complications
IVIG is associated with high costs that present barriers to payers and patients
Inferred Conclusions
IVIG appears more promising for acute COVID-19 management than for chronic post-viral conditions, suggesting timing of administration is critical
Optimization of IVIG dosing, administration timing, and patient selection criteria is needed before widespread clinical use in ME/CFS and PASC
Mechanisms of immune modulation through IVIG are well-characterized, but matching these mechanisms to specific patient phenotypes requires further research
Remaining Questions
Which ME/CFS patients are most likely to benefit from IVIG—are there biomarkers or immune profiles that predict response?
What This Study Does Not Prove
This review does not establish that IVIG is an effective standard treatment for ME/CFS—only that mixed results have been observed in small cohorts. The study does not clarify which ME/CFS patients might benefit most from IVIG or determine optimal dosing and timing. It also does not prove causation between IVIG administration and symptom improvement, as most evidence comes from uncontrolled or small studies.